cinacalcet HCl / Generic mfg. - LARVOL DELTA

Shenqi Yanshen Decoction protects against renal and bone injury in chronic kidney disease-mineral and bone disorder with potential involvement of Wnt5a/RhoA/Pkn3 signaling. (PubMed, J Ethnopharmacol) - "This study found that SQYSD exerts coordinated renal and skeletal protective effects in CKD-MBD, involving improvement of renal dysfunction, correction of mineral metabolic disorder, preservation of bone microarchitecture, and inhibition of the activation of osteoclasts. These effects may be partly associated with suppression of Wnt5a/RhoA/Pkn3-related signaling. The findings of this study provide pharmacological evidence supporting the traditional use of SQYSD in kidney-related bone disorders and suggest that it can serve as a complementary multi-target herbal intervention for CKD-MBD."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • RHOA • WNT5A

Challenging case of surgically refractory uraemic leontiasis ossea improving post kidney transplant (TTS 2026) - "This case represents the first reported case of surgically refractory ULO stabilised with cinacalcet before achieving durable control with kidney transplantation. Transplantation resulted in attenuation of skeletal deformities, marked improvement in bone density, and sustained clinical stability over 7 years."

Clinical • Endocrine Disorders • Transplantation

Treatment outcomes and allograft survival in kidney transplant recipient with tertiary hyperparathyroidism (TTS 2026) - "Recipients were classified into three groups: those receiving medical management (Cinacalcet), those undergoing parathyroidectomy (PTx), and those receiving no treatment... Although post-transplant tertiary hyperparathyroidism was associated with adverse graft and recipient outcomes, the treatment strategy did not significantly influence survival."

Clinical • Cardiovascular • Diabetes • Diabetic Nephropathy • Endocrine Disorders • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Transplant Rejection • Transplantation

Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up. (PubMed, J Clin Med) - " Etelcalcetide provided significantly greater, more sustained, and more consistent iPTH suppression than cinacalcet over 24 months, with additional benefits in mineral metabolism control. These findings support etelcalcetide as a potent therapeutic option for SHPT in hemodialysis patients and warrant confirmation in larger prospective trials."

Journal • Chronic Kidney Disease • Endocrine Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Comparative efficacy of interventions for vascular calcification and stiffness in dialysis patients:a systematic review and network meta-analysis. (PubMed, Cardiorenal Med) - "This study suggests that SUCRA rankings indicate STS has a potential comprehensive advantage in improving vascular stiffness and delaying calcification progression, making it a reasonable exploratory choice for dialysis patients with concurrent VC and VS. While EA ranks highest in SUCRA for reducing CAC volume score, it has limited impact on VS and requires caution regarding long-term safety. Given the limited sample size, network sparsity for some outcomes, and mostly non-significant between-group comparisons, large-scale, head-to-head RCTs are needed to further validate these findings."

Journal • Retrospective data • Review • Cardiovascular

Osteo-Men: Novel Combination Therapy for Osteoporosis in Men (clinicaltrials.gov) - P4 | N=40 | Completed | Sponsor: VA Office of Research and Development | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Osteoporosis • Rheumatology

Immunohistochemical Expression of CaSR, VDR, and AMA in Parathyroid Tumors in Relation to Hypercalcemia Severity in Primary Hyperparathyroidism. (PubMed, Curr Issues Mol Biol) - "No significant associations were identified between IHC marker expression and parameters of calcium-phosphorus metabolism, as well as cinacalcet treatment response...These findings suggest that alternative molecular mechanisms, rather than receptor expression levels, contribute to clinical heterogeneity. Further research is required."

Journal • Endocrine Disorders • Metabolic Disorders • Oncology • CASR • VDR

Calcimimetics and CaSR signaling in CKD-MBD: bone-immune-vascular crosstalk and therapeutic potential. (PubMed, Front Immunol) - "Calcimimetics, including cinacalcet, etelcalcetide, and evocalcet, are established CaSR-targeting therapies for secondary hyperparathyroidism in dialysis patients. We emphasize established clinical effects while distinguishing them from mechanistic hypotheses, including direct NLRP3 inflammasome suppression, Th17/Treg rebalancing, macrophage M1-to-M2 polarization, osteocyte connexin-43/DAMP regulation, and hematopoietic niche restoration, which remain insufficiently validated in human CKD. We propose an integrated bone-vascular-immune framework and identify biomarker-guided and precision-medicine strategies for future calcimimetic research."

Journal • Review • Chronic Kidney Disease • Endocrine Disorders • Inflammation • Nephrology • Orthopedics • Secondary Hyperparathyroidism • CASR • FGF23 • NFATC1 • NLRP3 • TNFRSF11B

A single-center retrospective cohort study of cinacalcet efficacy in uremic hemodialysis patients: Correlations with changes in parathyroid hormone, calcium and phosphorus over 12 months. (PubMed, Pak J Pharm Sci) - "Cin is more effective than Cal in helping uremic hemodialysis patients achieve composite control of iPTH and Ca × P. Therapeutic success correlates with reductions in iPTH and Ca and iPTH decline is closely linked to improved P levels, highlighting the importance of integrated management of SHPT."

Clinical • Journal • Retrospective data • Endocrine Disorders • Renal Disease • Secondary Hyperparathyroidism

Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "The optimal pharmacological strategy for SHPT depends on the WTP threshold. Cinacalcet is preferred at lower WTP levels, while etelcalcetide offers superior cost-effectiveness at higher WTP."

HEOR • Journal • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Secondary Hyperparathyroidism

Change in Bone Mineral Density After Parathyroidectomy for Secondary Hyperparathyroidism: A Review. (PubMed, J Clin Endocrinol Metab) - "PTx consistently improves BMD in patients with refractory secondary hyperparathyroidism, with the greatest gains at cancellous-rich skeletal sites. Clinicians should consider the skeletal benefits of PTx when counseling patients with medically refractory disease, particularly those with low baseline bone density and markedly elevated parathyroid hormone levels."

Journal • Chronic Kidney Disease • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Secondary Hyperparathyroidism

A Sustainable Hybrid (NH4)2SO₄-Driven SALLE-Fluorimetric On-Off Integrated Platform for the Determination of Cinacalcet HCl: A Calcium Receptors Sensing Drug in Different Matrices. (PubMed, Luminescence) - "Kinetic characterization was performed through Stern-Volmer modeling (KSV = 29.13 × 1012 L·mol-1·s-1 and dissociation constant, Kd = 6.90 × 10-6 M), double logarithmic plots (association constant, Ka = 1.45 × 105 L·mol-1), Scatchard analysis (K(Scatchard) = 4.32 × 105 M-1), and the Langmuir adsorption isotherm (K(Langmuir) = 8.51 × 104 ng/mL), all of which verified a specific, high-affinity drug-probe interaction. The platform was further applied to tablet uniformity testing and CC•HCl determination in human biological fluids."

Journal

Teriparatide in Combination with Cinacalcet May Improve Bone Mineral Density More Than Teriparatide Alone: A Randomized, Placebo-controlled Trial in Men with Low Bone Mass. (ASBMR 2026) - No abstract available

Clinical • Combination therapy

Pharmacological Management of Secondary Hyperparathyroidism in Dialysis Patients: A Narrative Review of Calcimimetics, Vitamin D Analogs, and Phosphate Binders. (PubMed, Cureus) - "Calcimimetics, particularly cinacalcet, reduce parathyroid hormone (PTH) by approximately 43% in hemodialysis patients without raising serum calcium, though hypocalcemia and gastrointestinal adverse effects limit tolerability. Intravenous etelcalcetide offers superior PTH suppression with improved gastrointestinal tolerability and eliminates oral adherence challenges through supervised dialysis-circuit administration...Novel agents including tenapanor offer complementary phosphate-lowering mechanisms with substantially reduced pill burden...A critical evidence gap exists in the GCC region, where diabetic nephropathy dominance, endemic vitamin D deficiency, and lower calcimimetic utilization may limit generalizability of existing trial data. Locally conducted research is urgently needed."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Endocrine Disorders • Metabolic Disorders • Nephrology • Secondary Hyperparathyroidism

Combination therapy with nutritional vitamin D and calcimimetics in secondary hyperparathyroidism: a mechanism-based approach to restoring PTH regulation. (PubMed, Front Nutr) - "However, current evidence remains largely based on surrogate biochemical endpoints. The Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, the largest Randomized Controlled Trial (RCT) of cinacalcet in dialysis patients, demonstrated no significant reduction in the primary composite endpoint of all-cause mortality or major nonfatal cardiovascular events in the intention-to-treat analysis despite consistent biochemical improvements, and the extent to which combination calcimimetic-based therapy translates into improved long-term clinical outcomes therefore remains uncertain."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Nephrology • Secondary Hyperparathyroidism • FGF23

Treatment of Hailey Hailey Disease with Oral Cinacalcet: A Case Report. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Genetic Disorders

Correcting serum phosphate homeostasis does not alleviate the health dangers of high phosphate consumption. (PubMed, J Transl Med) - "This work advances the understanding of the health impacts of Pi additives which are common in ultra-processed foods and common in the Western style diet. Specifically, the results produce clinically relevant findings that simply controlling serum Pi and/or Ca levels or Pi responsive endocrine factors such as FGF23, PTH, and osteopontin are not sufficient to block the negative impacts of chronic high dietary Pi consumption on the skeleton. Further, therapeutic strategies to control serum Pi have an impact on the kidneys in the context of high dietary Pi intake."

Journal • Inflammation • Nephrology • Orthopedics • Osteoporosis • Renal Disease • FGF23 • SPP1

The Effect of Teriparatide in a Brown Tumor Patient With Pathological Hip Fracture: A Case Report and Literature Review. (PubMed, JBJS Case Connect) - "To our knowledge, this is the first reported long-bone Brown tumor successfully treated with teriparatide."

Journal • Review • ANCA Vasculitis • Chronic Kidney Disease • Endocrine Disorders • Infectious Disease • Musculoskeletal Diseases • Nephrology • Oncology • Orthopedics • Pain • Renal Disease • Vasculitis

Concurrent Parathyroidectomy During Thyroidectomy in ESRD Patients: Risks, Benefits, and Long-Term Endocrine Outcomes in a Nationwide Cohort (AHNS 2026) - "Although concurrent parathyroidectomy decreases long-term cinacalcet use in ESRD patients undergoing thyroidectomy, it significantly increases the risk of acute and chronic PTH suppression, hypercalcemia episodes, and ongoing calcium and calcitriol supplementation. These findings support selective, indication-driven parathyroid resection during thyroidectomy and highlight the importance of counseling patients on the potential for long-term medication dependence and parathyroid insufficiency following concurrent surgery."

Clinical • Chronic Kidney Disease • Endocrine Disorders • Hypoparathyroidism • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Association of Parathyroidectomy with Incident Diabetes in Patients with Primary Hyperparathyroidism: A U.S. Multi-Institutional Cohort Study (AHNS 2026) - "Exclusion criteria included a history of MEN-1, MEN-2, secondary, tertiary, or other hyperparathyroidism (E21.1, E21.2, E21.3, E21.4, E21.5, N25.81, N25.89), thyroid or parathyroid neoplasms, dialysis, nephrectomy, or use of bisphosphonates, cinacalcet, thiazides, or lithium... Our findings suggest that parathyroidectomy is associated with lower odds of incident diabetes in patients with primary hyperparathyroidism. This association was consistent across all subgroups, including in adults over age 65. While more studies are needed, our findings suggest an additional benefit to consider in the definitive treatment of primary hyperparathyroidism."

Clinical • Diabetes • Endocrine Disorders • Metabolic Disorders

Wulingsan alleviates cisplatin-induced acute kidney injury and inhibits renal tubular epithelial cell apoptosis in association with the CaSR/CaMKKβ/AMPK pathway. (PubMed, Front Pharmacol) - "In vitro, WLS-containing serum reduced cisplatin-induced reactive oxygen species (ROS) production, intracellular Ca2+ overload, and apoptosis in mRTECs, effects reversed by the CaSR agonist cinacalcet. This study demonstrates that WLS protects against CP-induced kidney injury and inhibits apoptosis in renal tubular epithelial cells in association with the CaSR/CaMKKβ/AMPK pathway."

IO biomarker • Journal • Acute Kidney Injury • B Cell Lymphoma • Lymphoma • Nephrology • Oncology • Renal Disease • BAX • CASP3 • CASR • CCL2 • IL1B • TNFA

Parathyroid Hormone Receptor 1 Facilitates Cyst Growth in Genetic Models of Autosomal Dominant Polycystic Kidney Disease. (PubMed, J Am Soc Nephrol) - "These findings support a role for Pth1r as a ciliary GPCR linking systemic PTH signaling to cyst-promoting pathways in ADPKD."

Journal • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease • PKD1 • PKD2 • PRKD1

Adjudicating Heart Failure Events in Participants Receiving Hemodialysis: Findings from Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) Trial. (PubMed, Am J Nephrol) - "Roughly half of heart failure events reported by site investigators were not adjudicated as heart failure by the CEC. Site investigators failed to report additional events that were later adjudicated as heart failure endpoints. These findings suggest that, in the hemodialysis population, identifying and classifying heart failure events is challenging and highlight the importance of centralized adjudication to ensure specificity and consistency in clinical events ascertainment."

Journal • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Renal Disease • Secondary Hyperparathyroidism

Hypercalcemia in poorly differentiated endometrial cancer: a report of two cases. (PubMed, Gynecol Oncol Rep) - "In the second case, calcium and PTH levels improved with systemic chemotherapy and cinacalcet but recurred with disease progression, supporting a tumor-driven mechanism...Ectopic PTH secretion should be considered in patients with endometrial cancer presenting with hypercalcemia and elevated PTH in the absence of parathyroid pathology. Recognition of this rare entity is important to avoid misdiagnosis and to guide appropriate oncologic management."

Journal • Endocrine Disorders • Endometrial Cancer • Metabolic Disorders • Oncology • Solid Tumor

Low Dose Denosumab in the Management of Post-Transplant Tertiary Hyperparathyroidism (ENDO 2026) - "Transient post-operative hypercalcemia (11.6 mg/dL on post-op day 6), resolved by day 23 (calcium 8.4 mg/dL) with PTH 235 pg/mL, now suggestive of secondary hyperparathyroidism. In conclusion, low dose denosumab 30 mg may be an effective and safe option for treating post-transplant tertiary hyperparathyroidism with hypercalcemia refractory to cinacalcet, particularly when rapid calcium reduction is clinically necessary."

Post-transplantation • Acute Kidney Injury • Chronic Kidney Disease • Endocrine Disorders • Genito-urinary Cancer • Metabolic Disorders • Nephrology • Renal Calculi • Renal Cell Carcinoma • Renal Disease • Secondary Hyperparathyroidism • Solid Tumor • Transplantation